Exelixis (EXEL) said a phase 3 study showed its cabozantinib drug reduced the risk of disease progression or death by 50% compared with placebo in patients with advanced gastrointestinal neuroendocrine tumors
The study involved 116 patients with median progression-free survival of 8.5 months with cabozantinib compared with 5.6 months with placebo, the company said Friday in a statement.
The results "demonstrate the benefits of cabozantinib across a wide range of patients with neuroendocrine tumors and further underscore the potential of cabozantinib to become a much-needed new option," Exelixis Chief Medical Officer Amy Peterson said in the statement.
The US Food and Drug Administration is currently reviewing a supplemental new drug application for cabozantinib, the company said.
Shares of Exelixis fell 5.2% in late Friday trading. Earlier, Oppenheimer downgraded the stock to perform from outperform and cut the price target to $33 from $41.
Price: 32.34, Change: -1.79, Percent Change: -5.24
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。